Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17534686rdf:typepubmed:Citationlld:pubmed
pubmed-article:17534686lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:17534686lifeskim:mentionsumls-concept:C0025202lld:lifeskim
pubmed-article:17534686lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:17534686lifeskim:mentionsumls-concept:C0796392lld:lifeskim
pubmed-article:17534686lifeskim:mentionsumls-concept:C0021735lld:lifeskim
pubmed-article:17534686lifeskim:mentionsumls-concept:C1522484lld:lifeskim
pubmed-article:17534686lifeskim:mentionsumls-concept:C0036525lld:lifeskim
pubmed-article:17534686lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:17534686lifeskim:mentionsumls-concept:C0332173lld:lifeskim
pubmed-article:17534686pubmed:issue8lld:pubmed
pubmed-article:17534686pubmed:dateCreated2007-7-27lld:pubmed
pubmed-article:17534686pubmed:abstractTextVascular endothelial growth factor (VEGF) is a proangiogenic molecule produced by melanoma cells. We hypothesized that administration of bevacizumab (Bev), a monoclonal antibody that neutralizes VEGF, with low-dose interferon alfa-2b (IFN-alpha2b), an inhibitor of basic fibroblast growth factor (FGF), would lead to the regression of metastatic melanoma.lld:pubmed
pubmed-article:17534686pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17534686pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17534686pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17534686pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17534686pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17534686pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17534686pubmed:languageenglld:pubmed
pubmed-article:17534686pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17534686pubmed:citationSubsetIMlld:pubmed
pubmed-article:17534686pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17534686pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17534686pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17534686pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17534686pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17534686pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17534686pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17534686pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17534686pubmed:statusMEDLINElld:pubmed
pubmed-article:17534686pubmed:monthAuglld:pubmed
pubmed-article:17534686pubmed:issn1068-9265lld:pubmed
pubmed-article:17534686pubmed:authorpubmed-author:WalkerMichael...lld:pubmed
pubmed-article:17534686pubmed:authorpubmed-author:YoungDonnDlld:pubmed
pubmed-article:17534686pubmed:authorpubmed-author:VarkerKimberl...lld:pubmed
pubmed-article:17534686pubmed:authorpubmed-author:ChenHelen XHXlld:pubmed
pubmed-article:17534686pubmed:authorpubmed-author:CarsonWilliam...lld:pubmed
pubmed-article:17534686pubmed:authorpubmed-author:LesinskiGrego...lld:pubmed
pubmed-article:17534686pubmed:authorpubmed-author:JensenRhondaRlld:pubmed
pubmed-article:17534686pubmed:authorpubmed-author:KendraKariKlld:pubmed
pubmed-article:17534686pubmed:authorpubmed-author:LehmanAmyAlld:pubmed
pubmed-article:17534686pubmed:authorpubmed-author:KefauverChery...lld:pubmed
pubmed-article:17534686pubmed:authorpubmed-author:WuHaifengHlld:pubmed
pubmed-article:17534686pubmed:authorpubmed-author:BiberJennifer...lld:pubmed
pubmed-article:17534686pubmed:issnTypePrintlld:pubmed
pubmed-article:17534686pubmed:volume14lld:pubmed
pubmed-article:17534686pubmed:ownerNLMlld:pubmed
pubmed-article:17534686pubmed:authorsCompleteYlld:pubmed
pubmed-article:17534686pubmed:pagination2367-76lld:pubmed
pubmed-article:17534686pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:17534686pubmed:meshHeadingpubmed-meshheading:17534686...lld:pubmed
pubmed-article:17534686pubmed:meshHeadingpubmed-meshheading:17534686...lld:pubmed
pubmed-article:17534686pubmed:meshHeadingpubmed-meshheading:17534686...lld:pubmed
pubmed-article:17534686pubmed:meshHeadingpubmed-meshheading:17534686...lld:pubmed
pubmed-article:17534686pubmed:meshHeadingpubmed-meshheading:17534686...lld:pubmed
pubmed-article:17534686pubmed:meshHeadingpubmed-meshheading:17534686...lld:pubmed
pubmed-article:17534686pubmed:meshHeadingpubmed-meshheading:17534686...lld:pubmed
pubmed-article:17534686pubmed:meshHeadingpubmed-meshheading:17534686...lld:pubmed
pubmed-article:17534686pubmed:meshHeadingpubmed-meshheading:17534686...lld:pubmed
pubmed-article:17534686pubmed:meshHeadingpubmed-meshheading:17534686...lld:pubmed
pubmed-article:17534686pubmed:meshHeadingpubmed-meshheading:17534686...lld:pubmed
pubmed-article:17534686pubmed:meshHeadingpubmed-meshheading:17534686...lld:pubmed
pubmed-article:17534686pubmed:meshHeadingpubmed-meshheading:17534686...lld:pubmed
pubmed-article:17534686pubmed:meshHeadingpubmed-meshheading:17534686...lld:pubmed
pubmed-article:17534686pubmed:meshHeadingpubmed-meshheading:17534686...lld:pubmed
pubmed-article:17534686pubmed:meshHeadingpubmed-meshheading:17534686...lld:pubmed
pubmed-article:17534686pubmed:meshHeadingpubmed-meshheading:17534686...lld:pubmed
pubmed-article:17534686pubmed:meshHeadingpubmed-meshheading:17534686...lld:pubmed
pubmed-article:17534686pubmed:meshHeadingpubmed-meshheading:17534686...lld:pubmed
pubmed-article:17534686pubmed:meshHeadingpubmed-meshheading:17534686...lld:pubmed
pubmed-article:17534686pubmed:year2007lld:pubmed
pubmed-article:17534686pubmed:articleTitleA randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.lld:pubmed
pubmed-article:17534686pubmed:affiliationDivision of Surgical Oncology, The Ohio State University Comprehensive Cancer Center, N924 Doan Hall, 410 W 10th Avenue, Columbus, Ohio 43210, USA.lld:pubmed
pubmed-article:17534686pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17534686pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:17534686pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:17534686pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
pubmed-article:17534686pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17534686lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17534686lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17534686lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17534686lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17534686lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17534686lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17534686lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17534686lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17534686lld:pubmed